Magnetoliposomes are promising candidates for the development of selective drug delivery systems in the treatment of cancer. Those nanosystems were tested as carriers of a strong chemotherapeutic agent, doxorubicin, which is used against breast cancer. Herein, the magnetic properties of hydrophobic iron oxide nanoparticles located exclusively in the lipid bilayer were used to release this drug from the magnetoliposomes. The cytotoxic activity of the nanostructures against the normal and cancer cell lines was determined on the basis of cells viability measurement after incubation with different concentrations of these nanomaterials. In the same way, the effectiveness of killing cancer cells in combination with exposure to magnetic field was also evaluated. These experiments confirmed that the nanostructures composed of liposomes and magnetic nanoparticles are not cytotoxic. However, magnetoliposomes loaded with doxorubicin were effective and selective in reducing the viability of human breast tumor cell lines. In this paper, we demonstrated the promising application of the studied magnetoliposomes as carriers of doxorubicin released under the influence of magnetic field in tumor cells.

No abstract

No abstract

Tb3+‐substituted superparamagnetic iron‐oxide‐based nanoparticles (NPs) that can be promising for possible multimodal drug carrier and radiotherapy are presented. These NPs were obtained using a reverse micelle template method with controlled micelle size. The atomic ratio of Tb/Fe ions was found to be very close to that expected from the stoichiometry of the reagents used. Aqueous suspensions of Tb‐doped nanoferrites are emissive with emission peaks characteristic for the Tb3+ dopant. Time‐resolved fluorescence decay data revealed two populations occupying inequivalent matrix sites. Above 80 K the Tb‐doped nanoferrites were superparamagnetic, which is a prerequisite for their use as carriers in magnetic‐field‐driven targeted therapies. The incorporation of up to 15 at.% of Tb3+ in their core resulted in a decrease of magnetization. Nevertheless, this magnetization appears to be sufficient for their use as carriers in an external magnetic field, and, of equal importance, stable isotope 159Tb3+ could be replaced by radioactive 161Tb3+, yielding multimodal NPs, suitable for conjugated therapies such as radiotherapy and magnetothermal therapy, as well as targeted drug delivery.

The study aimed to synthesize and characterize the magnetic drug carrier modified with terbium (III) ions. The addition of terbium extends the possibilities of their applications for targeted anticancer radiotherapy as well as for imaging techniques using radioisotopes emitting β+, β−, α, and γ radiation. The synthesis of iron oxide nanoparticles stabilized with citrates using the co-precipitation method (IONP @ CA) was carried out during the experimental work. The obtained nanoparticles were used to synthesize a conjugate containing terbium ions and guanosine-5′-monophosphate as an analog of drugs from the thiopurine group. Conjugates and their components were characterized using Transmission Electron Microscopy, infrared spectroscopy, X-ray microanalysis, spectrofluorimetry, and thermogravimetric analysis. The hybrid was also investigated with Langmuir layers to check the interaction with analogs of biological membranes.